Breast Cancer — Highlights from the 2025 ESMO Annual Meeting | Breast Cancer Update

In this Cancer Conference Update podcast, Dr. Neil Love leads a discussion with Professor Giuseppe Carigliano and Dr. Priyanka Sharma about the key breast cancer papers presented at the 2025 ESMO Annual Meeting in Berlin. The panel reviews practice-changing presentations, focusing on HER2 positive, ER positive, and triple-negative breast cancer, and they discuss the use of both approved and non-approved agents and regimens. They analyze data from trials like DESTINY-Breast09 and DESTINY-Breast11, and they address the challenges of treatment sequencing, maintenance strategies, and managing toxicities. The experts share insights on adjuvant CDK inhibitor use, the role of oral SERDs, AKT targeting, and the management of metastatic triple-negative disease, incorporating case studies to illustrate clinical decision-making.

Outlines

Part 1: Introduction and HER2 Positive Breast Cancer

Part 2: Adjuvant Therapies and SERDs

Part 3: AKT and PI3K Pathway Targeting

Part 4: ER Positive, HER2 Negative Disease and ADC Management

Part 5: Triple Negative Breast Cancer and ADCs

Sign in to continue reading, translating and more.

Continue

Breast Cancer — Highlights from the 2025 ESMO Annual Meeting

Breast Cancer Update

Part 1: Introduction and HER2 Positive Breast Cancer

Introduction to ESMO 2025 Breast Cancer Updates and HER2 Positive Breast Cancer

Case Study: HER2 Positive, ER Positive Metastatic Breast Cancer

Destiny Breast 11 Study: Neoadjuvant TDXD for HER2-Positive Breast Cancer

Case Study: Triple Positive Breast Cancer with BRCA Mutation and Residual Disease

Part 2: Adjuvant Therapies and SERDs

Adjuvant CDK Inhibitors: MONARCH-E and NATALEE Studies

SERENA-6 Trial and the Use of Camisestrant

EMBRACA-3 Study: Imlunestrant and Abemaciclib Combination

EV-ERA Trial: Gerodestrant and Everolimus Combination

Part 3: AKT and PI3K Pathway Targeting

AKT Targeting: CAPItello-291 Study and the Use of Capivasertib

PI3K Pathway: Inavolisib Triplet Therapy

Victoria Study and SAC-TMT

Part 4: ER Positive, HER2 Negative Disease and ADC Management

Sequencing Strategies for ER Positive, HER2 Low/Negative Disease

Managing Tolerability Issues with TROP2 ADCs

Part 5: Triple Negative Breast Cancer and ADCs

GEPR-NOVA Trial and ASCENT03 Study

ASCENT03 and ASCENT04 Studies: Patient-Reported Outcomes and Treatment Strategies

TROPiCS-02 Study and ADC Options for Triple Negative Breast Cancer

Managing ILD and Final Thoughts on Metastatic Triple Negative Disease

Breast Cancer — Highlights from the 2025 ESMO Annual Meeting

Breast Cancer Update

Part 1: Introduction and HER2 Positive Breast Cancer

00:00Introduction to ESMO 2025 Breast Cancer Updates and HER2 Positive Breast Cancer

Introduction to ESMO 2025 Breast Cancer Updates and HER2 Positive Breast Cancer

05:17Case Study: HER2 Positive, ER Positive Metastatic Breast Cancer

Case Study: HER2 Positive, ER Positive Metastatic Breast Cancer

09:57Destiny Breast 11 Study: Neoadjuvant TDXD for HER2-Positive Breast Cancer

Destiny Breast 11 Study: Neoadjuvant TDXD for HER2-Positive Breast Cancer

15:03Case Study: Triple Positive Breast Cancer with BRCA Mutation and Residual Disease

Case Study: Triple Positive Breast Cancer with BRCA Mutation and Residual Disease

Part 2: Adjuvant Therapies and SERDs

20:48Adjuvant CDK Inhibitors: MONARCH-E and NATALEE Studies

Adjuvant CDK Inhibitors: MONARCH-E and NATALEE Studies

25:30SERENA-6 Trial and the Use of Camisestrant

SERENA-6 Trial and the Use of Camisestrant

30:30EMBRACA-3 Study: Imlunestrant and Abemaciclib Combination

EMBRACA-3 Study: Imlunestrant and Abemaciclib Combination

35:24EV-ERA Trial: Gerodestrant and Everolimus Combination

EV-ERA Trial: Gerodestrant and Everolimus Combination

Part 3: AKT and PI3K Pathway Targeting

40:17AKT Targeting: CAPItello-291 Study and the Use of Capivasertib

AKT Targeting: CAPItello-291 Study and the Use of Capivasertib

45:11PI3K Pathway: Inavolisib Triplet Therapy

PI3K Pathway: Inavolisib Triplet Therapy

50:28Victoria Study and SAC-TMT

Victoria Study and SAC-TMT

Part 4: ER Positive, HER2 Negative Disease and ADC Management

54:24Sequencing Strategies for ER Positive, HER2 Low/Negative Disease

Sequencing Strategies for ER Positive, HER2 Low/Negative Disease

1:00:02Managing Tolerability Issues with TROP2 ADCs

Managing Tolerability Issues with TROP2 ADCs

Part 5: Triple Negative Breast Cancer and ADCs

1:05:23GEPR-NOVA Trial and ASCENT03 Study

GEPR-NOVA Trial and ASCENT03 Study

1:10:58ASCENT03 and ASCENT04 Studies: Patient-Reported Outcomes and Treatment Strategies

ASCENT03 and ASCENT04 Studies: Patient-Reported Outcomes and Treatment Strategies

1:17:30TROPiCS-02 Study and ADC Options for Triple Negative Breast Cancer

TROPiCS-02 Study and ADC Options for Triple Negative Breast Cancer

1:22:01Managing ILD and Final Thoughts on Metastatic Triple Negative Disease

Managing ILD and Final Thoughts on Metastatic Triple Negative Disease